October 06, 2020; 95 (14) Correction
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
First published September 16, 2020, DOI: https://doi.org/10.1212/WNL.0000000000008927
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
Neurology Oct 2020, 95 (14) 661; DOI: 10.1212/WNL.0000000000008927
Citation Manager Formats
Make Comment
See Comments

In the article “Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients” by Plavina et al.,1 there is an error in the “Monocyte/VCAM-1 binding” key of figure 3. “Natalizumab continued” should have been represented by a green line and gray square; “Natalizumab interrupted” should have been represented by a red line and black circle. The editorial office regrets the errors.
Figure 3 Functional activity of CD3+ T cells, CD19+ B cells, and monocytes from RESTORE patients
- © 2020 American Academy of Neurology
Reference
- 1.↵
- Plavina T,
- Muralidharan KK,
- Kuesters G, et al
Disputes & Debates: Rapid online correspondence
No comments have been published for this article.
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.